Protara Therapeutics, Inc. (TARA): Price and Financial Metrics
TARA Price/Volume Stats
| Current price | $2.95 | 52-week high | $5.24 |
| Prev. close | $3.05 | 52-week low | $1.04 |
| Day low | $2.87 | Volume | 151,859 |
| Day high | $3.23 | Avg. volume | 215,397 |
| 50-day MA | $3.71 | Dividend yield | N/A |
| 200-day MA | $2.41 | Market Cap | 33.73M |
TARA Stock Price Chart Interactive Chart >
Protara Therapeutics, Inc. (TARA) Company Bio
Protara Therapeutics, Inc. operates as a biotech company. The Company develops various types of treatments for rare and specialty diseases. Protara Therapeutics serves customers in the State of New York.
Latest TARA News From Around the Web
Below are the latest news stories about PROTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate TARA as an investment opportunity.
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNew results from six patients with HGTa papillary tumors show five of six patients with HGRFS at Week 12Data continue to support favorable tolerability of TARA-002 in patients with NMIBCAs previously reported, anti-tumor activity observed in all three evaluable patients with CIS, including one heavily pre-treated BCG-unresponsive patient who achieved a complete responseCompany remains on track to report preliminary results from the expansion portion of the ADVANCED-1 trial in NMIBC patients with |
Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial ResultsCompany reports increased R&D expenses and a net loss, but remains optimistic about future milestones |
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateDosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS Company initiated Phase 2 trial of TARA-002 in Lymphatic Malformations Cash, cash equivalents and investments of $74M as of September 30, 2023 expected to fund operations into Q2 of 2025 NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Protara Therapeuti |
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs). “There is a pressing need for an effective FDA-approved therapy to treat LMs, a rar |
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in SituDosing is progressing on schedule in ongoing ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in its Phase 1b/2 ADVANCED-2 trial evaluating intravesical instillation of TARA-002, the Company’s investigatio |
TARA Price Returns
| 1-mo | -26.25% |
| 3-mo | 13.46% |
| 6-mo | 143.80% |
| 1-year | -8.67% |
| 3-year | -75.06% |
| 5-year | -82.44% |
| YTD | 57.32% |
| 2023 | -30.03% |
| 2022 | -60.30% |
| 2021 | -72.12% |
| 2020 | 47.62% |
| 2019 | -81.94% |
Loading social stream, please wait...